- RAK Hospital observes remarkable results: headache days reduced by 50-60% in a month, quality of life improved drastically
- Migraine is the second-highest cause of disability in the UAE
- Delay in diagnosis the biggest challenge in the treatment
Aiming to significantly reduce migraine-related headache days, neurologists at RAK Hospital are now using the new Anti-CGRP therapy, a specific treatment designed to cut down the frequency of headaches. The Anti-CGRP therapy targets CGRP – the protein known for causing migraine, reducing the frequency, severity, and duration of the headache episodes effectively. The treatment has already proved to be a huge success at RAK Hospital, showing a significant drop in migraine episodes by 50% to 60% every month.
Until now, in the absence of a specific preventive medication for migraine, doctors had been treating and managing the condition with the use of regular painkillers, triptans, other antidepressants, anti-epilepsy and anti-blood pressure drugs.
Often under diagnosed and untreated, Migraine is a highly disruptive, neurological disease that affects all aspects of a sufferer’s life, yet its impact on both personal and professional life is vastly undermined. It not only compromises a person’s way of life but also results in lost productivity while disabling the individual’s ability to carry out everyday tasks, many a times leading to stigma.
“The disability resulting from this chronic condition is tremendous, causing missed days of work and loss of ability to join family activities. The quality of life is disrupted heavily and patients spend almost 15 days a month suffering headaches which makes their life quite miserable. However, the new Anti-CGRP therapy is very well tolerated, applied in the form of self-administered injection it provides considerable benefits and already looks extremely promising with great outcome”, said Dr Raza Siddiqui, Executive Director, RAK Hospital.
The seriously debilitating condition is the second-highest cause of disability in the UAE. Nevertheless, the main challenge still remains the delay in diagnosis of the disease as its symptoms can usually be misinterpreted for other illnesses making it difficult to diagnose. It is indeed observed that in many cases, the diagnosis can take anywhere between 1 to 5 years from the first clinical manifestation of the disease and this can be attributed to factors including patient ignorance, self administration of drugs or delay in consulting the specialists. Therefore, it is advisable to consult the neurologists upon onset of migraine like symptoms to receive exact and quick diagnosis.
“Heralding a new era in the treatment of migraine, this novel therapy has given hope to millions of people suffering with the condition. We see over 100 patients a month in our OPD complaining of headaches and out of those around 60% turn out to be migraine patients. The use of the new anti-CGRP therapy has helped them experience improved quality of life within a short span of time as they experience significant reduction in the number of headache episodes every month”, commented Dr Sweta Adatia, Medical Director and Head of Department, Neurology, RAK Hospital.
“The response and clinical benefit is fast in this case whereas in case of typical preventive medications, we usually work up to the correct dose and then wait for 3-6 months to see whether they’re effective. These also work for patients who showed no results with the previous treatment protocols”, added Dr Adatia.
Migraine is a distinct neurological disease that is typically characterized by recurrent unilateral headache of moderate to severe pain intensity that can be described as throbbing in quality.It’s often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Migraine attacks can last for hours to days, and the pain can be so severe that it interferes with your daily activities.